Table 1. Risk of new onset metabolic dysfunction (T2D/hyperglycemia for post-SARS-CoV-2 patients).

Author	Study type	HR or OR (95% CI), comments
Aminian et al	Longitudinal COVID + 2800 pts	1.39 (1.13–1.71), for future Dx testing
Leong et al	Mendelian Random UKBio	1.14 (1.07–1.21), BMI and COVID-19 + severe
Xie et al	Cohort Study 180,000 VA Records	1.40 (1.36–1.44), incident DM of COVID-19+
Fernández-de-Las-Peñas	Case Control 299	1.06 (0.92–1.24), not significant DM risk
Barrett et al.	Two Retrospective Cohorts Record IQVIA, HealthVerity Covid+	2.66 (1.98–356) for DM (claims data)*1.31 (1.20–1.44) for DM (claims data)
Montefusco	Prospective 551 pts hospitalized	46% of COVID-19 + pts hyperglyc at 2 months

^*CDC MMWR report.